All stock lists
Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
Healthcare · Biotechnology
4.83+0.10 (+2.22%)
Insider Score
––Not scored
CSBR Insider Score
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
CSBR Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 |
| Revenue | 15.23 M | 13.84 M | 16.56 M | 15.04 M | 13.99 M | 12.36 M |
| Revenue Growth (YoY) | 8.84 % | 11.99 % | -2.82 % | 11.46 % | -0.47 % | -11.76 % |
| Cost of Revenue | 7.85 M | 6.81 M | 8.83 M | 7.26 M | 8.00 M | 7.27 M |
| Gross Profit | 7.38 M | 7.03 M | 7.72 M | 7.77 M | 6.00 M | 5.08 M |
| SG&A Expense | 5.76 M | 5.43 M | 5.64 M | 4.97 M | 4.42 M | 4.83 M |
| R&D Expense | 2.34 M | 2.12 M | 2.27 M | 2.62 M | 2.08 M | 1.96 M |
| Operating Expenses | 7.79 M | 7.66 M | 7.91 M | 7.59 M | 6.51 M | 6.80 M |
| Operating Income | -409.00 K | -631.00 K | -187.00 K | 185.00 K | -507.00 K | -1.71 M |
| Pretax Income | -415.00 K | -495.00 K | -237.00 K | 255.00 K | -452.00 K | -1.96 M |
| Tax Provision | 11.00 K | 172.00 K | 42.00 K | 18.00 K | 14.00 K | -129.00 K |
| Net Income | -426.00 K | -729.00 K | -279.00 K | 299.00 K | -466.00 K | -1.83 M |
| EPS (Basic) | -0.03 | -0.05 | -0.02 | 0.02 | -0.03 | -0.13 |
| EPS (Diluted) | -0.03 | -0.05 | -0.02 | 0.02 | -0.03 | -0.13 |
| Shares Outstanding | 13.90 M | 13.83 M | 13.89 M | 13.79 M | 13.79 M | 13.75 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.